middle.news
Noxopharm’s SOF-SKN Shows Multi-Day Skin Retention, Boosting Cutaneous Lupus Prospects
8:58am on Wednesday 22nd of April, 2026 AEST
•
Biotechnology
Read Story
Noxopharm’s SOF-SKN Shows Multi-Day Skin Retention, Boosting Cutaneous Lupus Prospects
8:58am on Wednesday 22nd of April, 2026 AEST
Key Points
SOF-16 half-life in skin approximately 3.5 days
Drug localised in epidermis and dermis with negligible bloodstream absorption
Findings support potential for less frequent dosing schedules
Data underpin preparations for upcoming human clinical trial
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Noxopharm (ASX:NOX)
OPEN ARTICLE